What is it? Why is it important?

An amendment during study conduct is a modification to a study that has already been approved by an Ethics Committee (EC) and, if applicable, Regulatory Authorities (RA), such as Swissmedic.

An amendment can either be:

  • Substantial, or
  • Non-substantial

 

Before being implemented, substantial amendments must receive approval from the EC and, if applicable, the RA.

If a change is needed to protect study participants, protective measures can be taken immediately, or as soon as possible, without waiting for approval.

 

Apart from affecting the study protocol, an amendment may result in changes to other EC approved study documents, such as the Participant Information Sheet (PIS) and the Informed Consent (ICF).

What do I need to do?

As a SP-INV, and based on issues encountered during study conduct:

  • Decide whether an amendment is necessary
  • Identify and adapt documents that may be affected by the protocol amendment, such as PIS/ICF, CRF.
  • Prepare amended documents and submit an amendment request to the EC and if applicable RA (e.g. Swissmedic)

 

Prepare the amended documents as follows:

  • Create the amended documents in a clean and track-change version
  • Adapt the document identification accordingly (e.g. date, version)
  • Summarize changes in a cover letter submitted together with the amended documents
  • Submit the amendment to EC, and if applicable RA, for approval

 

Implement substantial amendments only after EC/RA approval.

 

Preparing and submitting an amendment dossier to the EC/RA, as well as implementing the amendment, require additional resources such as staff time and funding. As a result, an amendment may raise study costs and lengthen the study duration.

Where can I get help?

Your local Research Support Centre↧ can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

External Links

Swissethics – see in particular

References

ICH GCP E6(R3) – see in particular guidelines

  • Glossary: Protocol definition
  • 2.5 Compliance with protocol
  • 3.12 Noncompliance
  • Appendix B. Clinical trial protocol and protocol amendment(s)

ISO 14155:2026 Medical devices – see in particular sections (access liable to cost)

  • 6.4 Clinical investigational plan (CIP)
  • 7.5.1 Amendments
  • 10.5 Informed consent process
  • 10.6 Compliance with the CIP
  • Annex A Clinical investigational plan

Swiss Law

ClinO – see in particular article and annex

  • Art. 29, 34, 55 Modifications
  • Annex 2 (bis 159)  Low-risk modifications

ClinO-MD – see in particular articles

  • 15, 20 Modifications

HRO – see in particular article

  • Art. 18 Modifications
Abbreviations
  • CIP – Clinical investigational plan
  • ClinO – Clinical Trials Ordinance
  • ClinO-MD – Ordinance on Clinical Trials with Medical Device
  • CRF – Case Report Form
  • CTU – Clinical Trials Unit
  • EC/RA – Ethics Committee / Regulatory Authorities
  • HRO – Human Research Ordinance
  • ICF – Informed Consent Form
  • ICH-GCP - International Council for Harmonisation - Good Clinical Practice
  • ISO – International Organization for Standardization
  • PIS – Participant Information Sheet
  • RA – Regulatory Authorities
Conduct ↦ Documents ↦ Required Documents ↦ Amendment
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Conduct ↦ Documents ↦ Required Documents ↦ Amendment